| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Inhibikase Therapeutics, Inc. | President & Head of R&D | Common Stock | 1.01M | $1.7M | $1.68 | 21 Feb 2025 | Direct |
| Zura Bio Ltd | CMO & Head of R&D | Class A Ordinary Shares | 162K | $648K | $4.00 | 18 May 2023 | Direct |
| Inhibikase Therapeutics, Inc. | President & Head of R&D | Stock Option (Right to Buy) | 1.1M | 21 Feb 2025 | Direct | ||
| Pulmatrix, Inc. | Director | Stock Option (Right to Buy) | 1.7K | 26 Jan 2023 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| IKT | Inhibikase Therapeutics, Inc. | 21 Feb 2025 | 0 | $0 | 3/A | President & Head of R&D | 28 Aug 2025, 19:52 |
| IKT | Inhibikase Therapeutics, Inc. | 21 Feb 2025 | 1 | $0 | 4/A | President & Head of R&D | 02 Jul 2025, 20:00 |
| ZURA | Zura Bio Ltd | 18 May 2023 | 1 | $0 | 4 | CMO & Head of R&D | 22 May 2023, 21:15 |
| ZURA | Zura Bio Ltd | 20 Mar 2023 | 0 | $0 | 3 | EVP and CMO | 21 Mar 2023, 19:33 |
| PULM | Pulmatrix, Inc. | 26 Jan 2023 | 1 | $0 | 4 | Director | 30 Jan 2023, 15:05 |
| PULM | Pulmatrix, Inc. | 27 Jan 2022 | 1 | $0 | 4 | Director | 31 Jan 2022, 08:36 |